4D Biomaterials has been awarded funding by Innovate UK for the development of a new class of liquid resins to improve wound healing following major surgery.
The company, which was formed as a spinout by University of Birmingham Enterprise and Warwick Innovations, is focused on developing its new polycarbonate-based resins, which can be custom-printed into bioresorbable 3D tissue scaffolds, providing accelerated and improved wound healing.
Having recently established a self-contained independent laboratory and office space in MediCity on the Boots site in Nottingham, the firm has made several senior appointments to advance its product development and operational capabilities.
The new head of R&D operations Dr Andrew Naylor will build operational capacity for the company, including capabilities for resin and device production, and testing and characterisation of resins and 3D printed parts. Naylor will be working with product development chemist Dr Siobhan Kilbride, who has first-hand experience of producing the resins in Birmingham’s laboratories.
4D Biomaterials is also now working with consultant Dr Phil Reeves, who is an experienced 3D printing technologist and strategist, having worked with global companies on additive manufacturing in the medical device sector.
CEO Philip Smith said: “Thanks to Innovate UK, we have been able to establish a fully-equipped laboratory at MediCity in which we will develop our product range and scale-up manufacture in preparation for a comprehensive pre-clinical testing programme.
“Andrew, Siobhan and Phil have brought a highly valuable mix of experience and talent to the team and have already made good progress in scaling production of the resins and developing designs for our first range of 3D printed medical devices.”
“The company has also made solid progress on the commercial front securing a first letter of intent from a potential customer in the US and a very encouraging response to independent market research covering three potential medical device applications.”
The business is now approaching potential investors with the aim of raising a further £1m to fund the next stage of product development and pre-clinical testing.